Our guest in this episode is James Dean Vogel, a recognized subject matter expert in bioprocessing and biotechnology with more than 40 years of experience across the biopharmaceutical, food, and cosmetic industries.

Jim is the founder and director of The BioProcess Institute, which he launched in 2007 to bring expert testing, training, and consulting together under one roof for the biopharmaceutical industry. Over the years, he's worked in leadership, project management, and engineering roles with companies like Amgen, GlaxoSmithKline, Sanofi‑Pasteur, Lipton, and Avon, including serving as lead designer for Amgen's Rhode Island facility.

Beyond industry, Jim is deeply committed to education. He's an Adjunct Professor at the University of Rhode Island, and has served as URI's Director of the Pharmaceutical Development Institute. He's also heavily involved in industry standards, serving on the ASME BioProcess Equipment Standard Committee, and holds degrees from Rutgers University and Manhattan College.

In this interview, host Samir Gondalia and Jim discuss the future of bioprocessing facilities, focusing on flexibility, digitalization, and innovations in cell and gene therapy manufacturing. Gain insights into designing adaptable facilities, the role of technology, and strategies to accelerate speed to market in the biotech industry. Look up https://multiplylabs.com/ and its co-founder/CEO Fred Parietti for the practical application of our discussion.

Key topics:
- Flexible facility design and renovation strategies
- Role of digitalization and wireless tech in biotech
- Challenges and solutions in cell and gene therapy manufacturing
- Impact of regulation and technology on speed to market

Quotable quotes:
- "Facility location impacts costs and delays."
- "Design for renovation, not obsolescence."

Jim can be reached via https://bioprocessinstitute.com/ or LinkedIn.

So, let's dive in with Jim Vogel.

Our guest in this episode is Richard Shah. Richard currently serves as a Project Director and heads up the US Global Engineering Dept at WuXi Biologics.

In this conversation on Design, Build and Deliver with Hart Companies with host Samir Gondalia, Richard shares his journey from being a chemist to leading global life science projects. He discusses the nuances of managing projects across different regions, the importance of site selection, and the evolving conversation around speed to market in the pharmaceutical industry. Richard also highlights the design drivers for biopharma facilities and the future technologies that will shape the industry, including the role of AI and digitalization. The discussion concludes with personal insights and reflections on the industry.

Takeaways
- Richard's transitioned from a chemist to a global engineering leader.
- Site selection involves multiple factors including tax incentives and labor market.
- Speed to market has become a critical focus post-COVID.
- Design drivers for biopharma include ESG, single-use technology, and digitalization.
- Flexibility and future-proofing are essential in facility design.
- Cost differentials exist between construction in the US and Ireland.
- Single-use technologies are preferred for speed and flexibility.
- Richard emphasizes the importance of continuous learning and adaptation.

Quotable quotes:
"Flexibility and future proofing are key."
"Good data is confidential."

Whether you are a global life science facilities leader or an industry follower, this episode is full of real-world insights and implementable tips.

The links to the various platforms are in comments.

My guest in this episode is George Skillin. George is VP of Strategy Services with Project Farma, a Perkin Elmer Company. George has over 35 years of BioPharmaceutical Experience in all aspects of manufacturing including Bulk Active Ingredient, Biotech Drug Substance, Aseptic Processing & Filling, Packaging and Serialization.

In this conversation, George and I discuss the intricacies of designing, building, and delivering life science facility projects. We explore the importance of speed and quality in project delivery, effective budget management, and the critical role of operational readiness. Our discussion also highlights changes in the industry post-COVID, the significance of local sourcing for talent, and the challenges of scaling up processes. Additionally, we touch on the potential impact of AI in validation and commissioning, future trends in facility design, and the need for robust training programs to address the talent shortage in the life sciences sector.

Key Takeaways:

• Good planning and scheduling are crucial for speed.
• Managing scope tightly minimizes project changes.
• Operational readiness should start during facility construction.
• Life science facilities are increasingly modular and prefabricated.
• Local sourcing of talent is becoming a priority.
• AI has potential but lacks real-world applications in validation.
• Training programs are essential for new hires in GMP environments.
• The industry faces a talent shortage as investments increase.
• Process development must align with facility capabilities.
• Future trends include a focus on smaller, more efficient facilities.

Quotable quotes:

• "Good planning and scheduling are crucial for speed."
• "Managing scope tightly minimizes project changes."
• "Local sourcing of talent is becoming a priority."

I have known George for many years and worked with him during our Pfizer days.
I thoroughly enjoyed talking to him in this chat. Hope you do too.

Here's George Skillin.